Vectormune FP ILT + AE Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - Κοτόπουλο - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

VECTORMUNE FP ILT+AE ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vectormune fp ilt+ae λυοφιλοποιημενο υλικο και διαλυτησ για ενεσιμο εναιωρημα

ceva-phylaxia veterinary biologicals co. ltd., budapest, hungary (0000010780) szallas u. 5,,,1107, budapest,,hu - avian encephalomyelitis virus, strain calnek 11 (ae); live recom. fowlpox virus expressing the membrane fusion protein & the enca/tion protein of avian inf. laryngotracheitis - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 200mg/tab - avian encephalomyelitis virus, strain calnek 11 (ae) 0,00 ly.insp.sv 0; live recom. fowlpox virus expressing the membrane fusion protein & the enca/tion protein of avian inf. laryngotracheitis 0,00 ly.insp.sv 0 - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ - Ορνίθια - Χρόνοι αναμονής: Ορνίθια 0 Ημέρες Κρέας και εδώδιμοι ιστοί

VECTORMUNE FP ILT ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vectormune fp ilt λυοφιλοποιημενο υλικο και διαλυτησ για ενεσιμο εναιωρημα

ceva-phylaxia veterinary biologicals co. ltd., budapest, hungary (0000010780) szallas u. 5,,,1107, budapest,,hu - live recom. fowlpox virus expressing the membrane fusion protein & the enca/tion protein of avian inf. laryngotracheitis - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - live recom. fowlpox virus expressing the membrane fusion protein & the enca/tion protein of avian inf. laryngotracheitis 0,00 ly.insp.sv 0 - Ορνίθια - Χρόνοι αναμονής: Ορνίθια 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Vectormune FP ILT Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vectormune fp ilt

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - Κοτόπουλο - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Innovax-ND-ILT Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

innovax-nd-ilt

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - Ανοσολογικά φάρμακα - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Prevexxion RN+HVT+IBD Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

prevexxion rn+hvt+ibd

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - Κοτόπουλο - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Ultifend ND IBD Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

ultifend nd ibd

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - Ανοσολογικά φάρμακα - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Mhyosphere PCV ID Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

HIPRABOVIS IBR MARKER LIVE ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

hiprabovis ibr marker live λυοφιλοποιημενο υλικο και διαλυτησ για ενεσιμο εναιωρημα

lab. hipra s.a., amer-girona, spain (0000007652) avda la selva, 135,e-17170,amer,es - live ge tk double-gene deleted bovine herpes virus type 1 (bohv-1), strain ceddel - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - live ge tk double-gene deleted bovine herpes virus type 1 (bohv-1), strain ceddel 0,00 ly.insp.sv 0 - bovine rhinotracheitis virus (ibr) - Βοοειδή - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί

NOBILIS SE LIVE 1 to 6 x 10^8 cfu/dose ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΓΙΑ ΧΟΡΗΓΗΣΗ ΜΕ ΠΟΣΙΜΟ ΝΕΡΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

nobilis se live 1 to 6 x 10^8 cfu/dose λυοφιλοποιημενο υλικο για χορηγηση με ποσιμο νερο

intervet international bv (boxmer), holland (0000005707) wim de körverstraat 35,5831 an boxmeer,boxmeer,nl - live attenuated salmonella enterica subsp.enterica serovar enteritidis strain cal10 sm+/rif+/ssq - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΓΙΑ ΧΟΡΗΓΗΣΗ ΜΕ ΠΟΣΙΜΟ ΝΕΡΟ - 1 to 6 x 10^8 cfu/dose - live attenuated salmonella enterica subsp.enterica serovar enteritidis strain cal10 sm+/rif+/ssq 0,00 ly.us.dr.w 1 to 6 x 10^8 cfu/dose - salmonella - Όρνιθες - Χρόνοι αναμονής: Όρνιθες 28 Ημέρες Κρέας και εδώδιμοι ιστοί